# Huons

> Huons is a VC fund in Seongnam backing Biotechnology, Medical and Pharmaceutical. See 11 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Seongnam, South Korea
- Total investments: 11
- Last investment: Jul 2026
- Lead investor: 18%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/huons/
- Website: http://huons.com/web/home.php

Huons is a VC fund in Seongnam focused on Biotechnology and Medical. Huons has manufactured the high quality finished products since 1965 and developed first local anesthetics and plastic ampoule injection in Korea. they are doing their best to supply high quality products through strict quality control system and continued R&D efforts based on the technologies and know-how accumulated. Huons has been exportingtheir finished pharmaceutical products to about 30 countries including N/S.America, Europe, Japan, Asia, and Africa.

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $6.7M–$24M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 55% |
| Medical | 4 | 36% |
| Pharmaceutical | 4 | 36% |
| Health Care | 2 | 18% |
| Therapeutics | 2 | 18% |

16 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 36% |
| Seed | 2 | 18% |
| Series B | 2 | 18% |
| Venture - Series Unknown | 2 | 18% |
| Convertible Note | 1 | 9% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| South Korea | 9 | 82% |
| United States | 1 | 9% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| ArcGen Bioscience | ArcGen Bioscience is a biopharmaceutical development company focused on researching, developing, and advancing innovative therapeutic solutions to address unmet medical needs through cutting-edge biotechnology and drug development. | $6.7M | Series A | Jul 13, 2026 |  |
| Aliad Biopharma | Aliad Biopharma is a biotechnology company focused on developing small-molecule therapeutics targeting mTORC2 pathways. Its research aims to address age-related and degenerative diseases, including neurological and muscle disorders. The company leverages advanced biomedical science to design targeted treatments and expand possibilities in drugdevelopment and translational research. |  | Seed | Nov 15, 2024 |  |
| BreezeBio | GenEdit was founded to transform the delivery of gene therapies and enable the next generation of non-viral, gene editing-based therapeutics. GenEdit’s proprietary technology, NanoGalaxy™ platform solves current delivery challenges by systematically screening its nanoparticle library and providing safer and efficient delivery to target tissues. Thecompany's tool makes therapeutic gene editing possible and is easier to use, faster and more accurate than previous gene-editing techniques and thus has the potential for a wide range of therapeutic applications, enabling physicians to cure incurable genetic diseases. | $24M | Series A | Jan 23, 2024 |  |
| Generate great Experiance | Generate great Experiance is an IT company that develops IoT equipment for medical platform. | $4.7M | Convertible Note | Dec 06, 2023 |  |
| CellBion | CellBion specializes in radiopharmaceuticals and radioligand therapy. The company's services include diagnostic drug and medication research and development for cardiovascular diseases, inflammation, prostate cancer, imaging agents for bones, and kidney scintigraphy. | $5.9M | Venture - Series Unknown | Oct 25, 2023 |  |
| Mthera Pharma | Mthera Pharma is a biopharmaceutical research and development company. |  | Series B | Dec 24, 2021 |  |
| PharmCADD | Uses AI-based protein structure prediction algorithms, MD simulation, and Quantum calculation to enable faster drug design. | $16M | Series B | Apr 19, 2021 |  |
| Master Meditech | Master Meditech is a venture company that discovers new drugs with protein structure identification and medicinal chemistry. | $7.1M | Series A | Mar 31, 2021 |  |
| Mthera Pharma | Mthera Pharma is a biopharmaceutical research and development company. |  | Seed | Dec 28, 2020 |  |
| NovaCell Technology | NovaCell Technology produces biomaterials using peptide libraries and proteome profiling technology, it selects potential peptide and biomarker candidates from a set of model systems. It creates biopharmaceuticals and biomaterials based on technologies for proteomics and peptide libraries. | $11.2M | Venture - Series Unknown | Sep 21, 2020 |  |

10 of 11 investments shown.

## Co-investors
- [Dayli Partners](https://shizune.co/investors/profile/dayli-partners) — VC Fund, 3 deals together
- [KIMCO](https://shizune.co/investors/profile/kimco-f8f1) — VC Fund, 2 deals together
- [SGI Venture Capital](https://shizune.co/investors/profile/sgi-venture-capital) — VC Fund, 2 deals together
- [ACVC](https://shizune.co/investors/profile/acvc) — VC Fund, 1 deal together
- [Aion Investment Management](https://shizune.co/investors/profile/aion-investment-management) — VC Fund, 1 deal together
- [CP Partners](https://shizune.co/investors/profile/cp-partners) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund
- [British Business Investments](https://shizune.co/investors/profile/british-business-investments) — VC Fund
- [White Star Capital](https://shizune.co/investors/profile/white-star-capital) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Strong Ventures](https://shizune.co/investors/profile/strong-ventures) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund
- [Kakao Ventures](https://shizune.co/investors/profile/kakao-ventures) — VC Fund

## Featured in investor lists
- [FinTech Investors in South Korea](https://shizune.co/investors/fintech-investors-south-korea)
- [Venture Capital VC Funds in South Korea](https://shizune.co/investors/venture-capital-vc-funds-south-korea)
- [Medical VC Funds in South Korea](https://shizune.co/investors/medical-vc-funds-south-korea)
- [Venture Capital Investors in South Korea](https://shizune.co/investors/venture-capital-investors-south-korea)

## FAQ

### What does Huons invest in?

Huons invests primarily in Biotechnology, Medical and Pharmaceutical startups, most often at Series A and Seed stage. Most of the 11 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Huons's check size?

Huons typically joins rounds of $6.7M–$24M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Huons participates in.

### When did Huons last invest?

The most recent investment recorded for Huons closed in Jul 2026. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co